STK39 and breast cancer: MiR-299 showed low expression in BC and directly targeted serine/threonine kinase 39 (STK39), knockdown of STK39 suppressed epithelial–mesenchymal transition markers and matrix metalloproteinase expression, and inhibited cell migration and invasion [21].